Cargando…
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes. Here, we comprehensively profile the genomic landscape of 42 benign and malignant tumors across 13 individua...
Autores principales: | Davies, Helen R., Hodgson, Kirsty, Schwalbe, Edward, Coxhead, Jonathan, Sinclair, Naomi, Zou, Xueqing, Cockell, Simon, Husain, Akhtar, Nik-Zainal, Serena, Rajan, Neil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797807/ https://www.ncbi.nlm.nih.gov/pubmed/31624251 http://dx.doi.org/10.1038/s41467-019-12746-w |
Ejemplares similares
-
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial
por: Danilenko, Marina, et al.
Publicado: (2018) -
Overexpression of MYB drives proliferation of CYLD‐defective cylindroma cells
por: Rajan, Neil, et al.
Publicado: (2016) -
Genetic Testing in CYLD Cutaneous Syndrome: An Update
por: Nagy, Nikoletta, et al.
Publicado: (2021) -
Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells
por: Rouhani, Foad J., et al.
Publicado: (2022) -
p63 and smooth muscle actin expression in low‐grade spiradenocarcinomas in a case of CYLD cutaneous syndrome
por: Hoyle, Aoisha, et al.
Publicado: (2018)